Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2025 results on April 24, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $10.74 billion and $1.54 per share, respectively.Earnings estimate for 2025 has increased to $6.78 from $6.75 per share over the past 30 days, while that for 2026 has decreased to $6.06 from $6.08. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchBMY’s ...

Core Viewpoint - Gilead Sciences, Inc. (GILD) and Bristol Myers Squibb (BMY) are prominent biotechnology companies with diverse portfolios and global reach, each presenting unique investment opportunities and challenges [1][2][3]. Gilead Sciences (GILD) - Gilead is a leader in the HIV treatment market, with its flagship drug Biktarvy being the most prescribed regimen for HIV-1 infection, maintaining a growing market share [4]. - The company’s prevention drug, Descovy, holds over 40% market share in the U.S. for pre-exposure prophylaxis (PrEP) [4]. - Late-stage studies for lenacapavir, a potential twice-yearly HIV prevention treatment, could significantly enhance Gilead's HIV portfolio [5]. - Gilead's oncology segment includes the successful breast cancer drug Trodelvy, which is undergoing further label expansion studies [6]. - The liver disease portfolio has been bolstered by the FDA approval of seladelpar for primary biliary cholangitis, enhancing Gilead's offerings in this area [7]. - As of December 31, 2024, Gilead's total debt-to-total-capital ratio was 59%, with $10 billion in cash and long-term debt of $25 billion [8]. Bristol Myers Squibb (BMY) - BMY's Growth Portfolio, including drugs like Reblozyl and Opdualag, has stabilized revenue amidst generic competition, with Reblozyl showing strong performance [9][10]. - Opdivo continues to gain momentum with consistent label expansions, and the recent FDA approval for subcutaneous use is expected to enhance its immuno-oncology franchise [11]. - BMY has made strategic acquisitions to expand its portfolio, including the recent approval of Cobenfy for schizophrenia, validating its acquisition strategy [12]. - Despite the growth from newer drugs, BMY faces challenges from generic competition affecting legacy drugs, which significantly impact revenue [13]. - As of December 31, 2024, BMY's total debt-to-total-capital ratio was 75.2%, with cash and equivalents of $10.3 billion and long-term debt of $47.6 billion [14]. Financial Estimates and Performance - The Zacks Consensus Estimate for GILD's 2025 sales indicates a slight decrease of 0.39%, while EPS is expected to increase by 70.13% [15]. - In contrast, BMY's 2025 sales are projected to decrease by 5.11%, but EPS is anticipated to rise by 489.57% [18]. - GILD has outperformed BMY in price performance, with a gain of 15.2% compared to BMY's loss of 9.6% year-to-date [22]. - Valuation metrics show GILD trading at a forward P/E ratio of 13.23, higher than BMY's 7.61 [22]. - BMY offers a higher dividend yield of 4.83% compared to GILD's 2.97% [24]. Investment Outlook - Gilead's innovation in its HIV portfolio and potential approval of lenacapavir for HIV prevention are seen as strong growth catalysts [25]. - BMY's efforts to counteract generic competition are noted, but the outlook for 2025 appears challenging [26]. - Overall, GILD is considered a more favorable investment option at present due to its solid fundamentals and growth potential despite its higher valuation [26].

Group 1 - Bristol Myers Squibb (BMY) faced a setback in the late-stage ODYSSEY-HCM study for its cardiovascular drug Camzyos (mavacamten), which did not meet its dual primary endpoints [1][2][5] - The study aimed to evaluate changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2) at week 48, but failed to show significant improvements [2][5] - Following the disappointing results, BMY's stock declined by 7.2% year to date, while the industry saw a decline of 8.4% [2] Group 2 - Camzyos is a selective, reversible, allosteric inhibitor of cardiac myosin, indicated for symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM), with sales totaling $602 million in 2024 [4] - The ODYSSEY-HCM trial enrolled 580 adult patients and tested the hypothesis that a cardiac myosin inhibitor would improve patient measures, but no new safety signals were observed despite the disappointing results [5] - Concerns about the efficacy of cardiac myosin inhibitors in non-obstructive hypertrophic cardiomyopathy (nHCM) were raised, affecting shares of Cytokinetics, which is developing a similar drug [6] Group 3 - BMY's Growth Portfolio includes drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, which have stabilized revenue amid generic competition [7] - Label expansions for these drugs are expected to further boost sales, with Opdivo maintaining momentum through consistent label expansions [8] - BMY has also broadened its portfolio with the FDA approval of xanomeline and trospium chloride for schizophrenia treatment under the brand name Cobenfy [9] Group 4 - BMY agreed to acquire 2seventy Bio, Inc. for $286 million, sharing profits and losses related to the development and commercialization of Abecma in the U.S. [10] - The company currently holds a Zacks Rank 3 (Hold), with better-ranked stocks in the biotech sector including Amicus Therapeutics and ANI Pharmaceuticals, both rated 1 (Strong Buy) [11]

Group 1: Stock Performance - Bristol Myers Squibb (BMY) stock closed at $53.78, showing a +1.34% change from the previous day's closing price, but lagged behind the S&P 500's daily gain of 9.52% [1] - The stock has decreased by 13.72% over the past month, which is worse than the Medical sector's loss of 14.16% and the S&P 500's loss of 13.47% [1] Group 2: Upcoming Earnings - The earnings report for Bristol Myers Squibb is anticipated on April 24, 2025, with expected earnings of $1.55 per share, reflecting a year-over-year growth of 135.23% [2] - Revenue is projected to be $10.69 billion, indicating a 9.94% decline from the same quarter last year [2] Group 3: Full Year Estimates - For the full year, earnings are estimated at $6.75 per share, representing a +486.96% change from the previous year, while revenue is projected at $45.59 billion, showing a -5.6% change [3] Group 4: Analyst Estimates - Recent changes in analyst estimates for Bristol Myers Squibb suggest a positive outlook on the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which reflects these estimate changes, indicates a current rank of 3 (Hold) for Bristol Myers Squibb [6] Group 5: Valuation Metrics - Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.86, which is below the industry average Forward P/E of 15.86 [7] - The company has a PEG ratio of 1.97, compared to the industry average PEG ratio of 1.31, indicating a relatively higher valuation based on anticipated earnings growth [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [8][9]

Core Viewpoint - Bristol Myers Squibb (BMY) has received FDA approval for the label expansion of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adult and pediatric patients aged 12 years and older [1][2] Company Developments - The latest FDA approval converts the previous accelerated approval for Opdivo monotherapy in the second-line setting to full approval and expands the indication for Opdivo plus Yervoy into the first-line treatment [2] - The approval was based on the phase III CheckMate-8HW study, which showed that Opdivo plus Yervoy met the dual primary endpoints of progression-free survival compared to Opdivo monotherapy and chemotherapy [4][5] - Opdivo plus Yervoy demonstrated a 79% reduction in the risk of disease progression or death compared to chemotherapy in the first-line setting and a 38% reduction versus Opdivo monotherapy across all lines of therapy [5] - The approval was granted more than two months ahead of the target action date of June 23, 2025, with ongoing studies assessing various secondary endpoints, including overall survival [6] Market Performance - BMY shares have increased by 7.9% over the past year, contrasting with a 20% decline in the industry [3] Portfolio Expansion - The approval of Opdivo continues to enhance BMY's immuno-oncology portfolio, with expectations for sustained impact into the next decade [7] - BMY's growth portfolio, which includes drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, has stabilized revenue amid generic competition for legacy drugs [10] - The company has also recently acquired 2seventy bio, Inc. for $286 million, sharing profits and losses related to the development of Abecma in the U.S. [12]

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Biopharma in North America - **Market Analysis**: The latest weekly Total Prescription (TRx) year-over-year (YoY) growth for the week ending March 28, 2025, was +2.1%, a decrease from +2.5% the previous week and +3.1% over the past 12 weeks [1][2] Core Insights - **TRx Growth**: For the week ended March 28, the US total market weekly TRx YoY change was +2.1%, compared to +0.4% a year ago. The rolling 4-week TRx YoY was +2.9%, and the rolling 12-week TRx YoY was +3.1% [2] - **Extended Unit Growth**: Extended unit (EUTRx) weekly YoY growth was +0.7%, which is below the TRx YoY growth [2] - **Sequential Growth**: Sequential weekly TRx growth was -1.8%, compared to -1.5% the week before [2] Company-Specific Developments - **Bristol Myers Squibb (BMY)**: - Cobenfy, approved for schizophrenia on September 26, 2024, had approximately 1,570 scripts for the week, up from ~1,440 the previous week. To meet 2025 consensus expectations, Cobenfy TRx needs to track at ~2-3 times the volumes from recent schizophrenia launches [3] - The consensus estimate for Cobenfy has declined to $160 million from $196 million, implying ~125K TRx are required to meet this estimate [3] - **Vertex Pharmaceuticals (VRTX)**: - Journavx, approved for acute pain on January 30, 2025, recorded approximately 2,230 scripts for the week, up from ~1,760 the previous week. To achieve the 2025 sales estimate of $87 million, approximately 229K and 441K total scripts are needed for 14-day and 7-day script durations, respectively [4] Competitive Landscape - **Biosimilars**: The TRx share chart for Stelara biosimilars was added, with Amgen's Wezlana launched on January 17, 2025, and Teva/Alvotech's Selarsdi launched on February 21, 2025 [5] - **Launch Comparisons**: A comparison chart for Descovy vs. Apretude was added, with anticipation for FDA approval of GILD's Lenacapavir [8] Seasonal Trends - **Vaccine Tracking**: Seasonal respiratory vaccine tracking exhibits were added, noting that RSV vaccine volumes are tracking ~65% below last year's levels, and COVID vaccine volumes are also down year-over-year [9] Notable Drug Performance - **Key Products**: - Mounjaro and Zepbound from Eli Lilly are being tracked, with Mounjaro showing significant growth [10] - The oral psoriasis market is being monitored, particularly BMY's Sotyktu launch against AMGN's Otezla [10] Pricing and Market Dynamics - **Immunology Pricing Analysis**: Updated charts for 4Q24 show how volume from additional indications impacts price per script for various drugs [11] - **Biosimilar Adoption**: Comprehensive analysis of biosimilar adoption across various branded drugs was presented [12] Additional Insights - **Market Trends**: The IQVIA databases differentiate between prescription and sales trends, with TRx representing total prescriptions dispensed, including refills [27] - **Sales Dynamics**: The report emphasizes that IQVIA sales dollars reflect list prices and do not account for rebates or discounts, indicating a need for careful interpretation of sales data [43] This summary encapsulates the key points from the conference call, highlighting industry trends, company-specific developments, and competitive dynamics within the biopharma sector.

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout. That's why it's always important to assess the safety of a dividend before relying on it, especially when that yield is well above average.Healthcare giant Bristol Myers ...

Core Viewpoint - Bristol Myers Squibb (BMY) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the approval of Opdivo (nivolumab) for additional indications in treating non-small cell lung cancer (NSCLC) and for a subcutaneous formulation across multiple solid tumor indications [1][10]. Group 1: Opdivo Approval and Clinical Trials - The CHMP recommended Opdivo in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Opdivo as monotherapy after surgical resection for high-risk resectable NSCLC patients with PD-L1 expression ≥1% [2]. - The positive CHMP opinion was based on the CheckMate-77T trial, which showed significant improvement in event-free survival compared to neoadjuvant chemotherapy and placebo [3]. - The CheckMate-77T study also demonstrated improvements in secondary efficacy endpoints, including pathologic complete response and major pathologic response (MPR) [4]. Group 2: Market Performance and Growth - BMY's shares have increased by 21.4% over the past year, contrasting with a 7.1% decline in the industry [9]. - The approval of Opdivo Qvantig for subcutaneous use is expected to enhance the immuno-oncology franchise's impact into the next decade [12]. - BMY's growth portfolio, including drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, has stabilized revenue amid generic competition [13]. Group 3: Recent Acquisitions and New Approvals - BMY recently acquired 2seventy bio, Inc. for $286 million, with plans to close the acquisition in the second quarter of 2025 [15]. - The approval of Cobenfy for schizophrenia represents a new pharmacological approach, with initial sales of $10 million in 2024 expected to contribute significantly to BMY's revenue [14].

Group 1: Bristol Myers Squibb - Bristol Myers Squibb is trading at a forward price-to-earnings (P/E) multiple of just 9, significantly lower than the S&P 500 average of 21 [2] - The company faces challenges such as multiple patent cliffs and a high long-term debt of $47.6 billion, compared to cash and marketable securities of $11.2 billion [3] - Despite risks, the company has secured approvals for two potential blockbuster drugs, Cobenfy and Breyanzi, which could generate substantial revenue [4] - The dividend payout ratio is 60%, supporting a 4% yield, making it attractive for dividend-focused investors [5] Group 2: United Parcel Service (UPS) - UPS has seen a 25% decline in stock price over the past year, resulting in a forward P/E multiple of less than 15 [6] - The company reported a profit of $5.8 billion on revenue of $91.1 billion last year, despite struggles in growth [7] - The payout ratio is around 100%, but free cash flow of $6.2 billion exceeds the $5.4 billion paid out in dividends, indicating a safe payout [8] - UPS offers a high yield of 5.7%, making it appealing for income investors [8] Group 3: Dell Technologies - Dell Technologies trades at a low forward P/E multiple of 10, with significant growth opportunities in artificial intelligence (AI) [9] - The server and networking business reported 54% sales growth in the most recent fiscal year [10] - The stock has a 2.2% dividend yield with a modest payout ratio of 28%, allowing for both dividend payments and growth investments [11]

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses the author's personal opinions and does not reflect any business relationships with the companies discussed [2].